US PTO re-examines Singulair patent after online community searches for prior art
03 June 2009
Nancy Faigen
Please Login to read the full article.
03 June 2009
Nancy Faigen
The US Patent & Trademark Office has ordered a re-examination of
Merck & Co's US patent No 5,565,473, covering the active ingredient in its top-selling asthma drug Singulair (montelukast sodium) tablets, saying that new questions of patentability have been raised by a New York-based company...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Medicines Co shares rise 12% on US settlement with Teva on Angiomax patents
- Pfizer's 'non obvious' Viagra patents good until 2019 to fend off Teva in US
- US Capitol Capsule: Supreme Court to weigh generic drug liability, patent burden-of-proof standards
- Glenmark launches 'skinny labelled' generic levocetirizine in the US
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
